Prostaglandin E2 stimulates Fas ligand expression via the EP1 receptor in colon cancer cells

British Journal of Cancer

Volumn 99, Issue 3, 2008, Pages 502-512

  O'Callaghan, G ^a   Kelly, J ^a   Shanahan, F ^a   Houston, A ^a  

^a University College Cork and INFANT Centre   (Ireland)

Author keywords

Fas ligand; Prostaglandin E2; Regulation; Tumour immune evasion

Indexed keywords

CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; FAS LIGAND; PROSTAGLANDIN E1; PROSTAGLANDIN E2; PROTEIN; MESSENGER RNA; PROSTAGLANDIN E RECEPTOR; PROSTANOID RECEPTOR EP1;

ARTICLE; CANCER CELL; CELL STRAIN HT29; COLON CANCER; CYTOTOXICITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEUKEMIA CELL LINE; PRIORITY JOURNAL; RNA INTERFERENCE; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE; TUMOR CELL; COCULTURE; COLON TUMOR; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL LINE, TUMOR; COCULTURE TECHNIQUES; COLONIC NEOPLASMS; DINOPROSTONE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FAS LIGAND PROTEIN; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; RECEPTORS, PROSTAGLANDIN E; RNA INTERFERENCE; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 48349146366     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604490     Document Type: Article

References (40)

1. Barnhart BC, Legembre P, Pietras E, Bubici C, Franzoso G, Peter ME (2004) CD95 ligand induces motility and invasiveness of apoptosis-resistant tumor cells. EMBO J 22: 22
2. Belluco C, Esposito G, Bertorelle R, Alaggio R, Giacomelli L, Bianchi LC, Nitti D, Lise M (2002) Fas ligand is up-regulated during the colorectal adenoma - carcinoma sequence. Eur J Surg Oncol 28: 120-125
3. Bennett MW, O'Connell J, Houston A, Kelly J, O'Sullivan GC, Collins JK, Shanahan F (2001) Fas ligand upregulation is an early event in colonic carcinogenesis. J Clin Pathol 54: 598-604
4. Bos CL, Richel DJ, Ritsema T, Peppelenbosch MP, Versteeg HH (2004) Prostanoids and prostanoid receptors in signal transduction. Int J Biochem Cell Biol 36: 1187-1205
5. Cao Y, Prescott SM (2002) Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J Cell Physiol 190: 279-286
6. Chulada PC, Thompson MB, Mahler JF, Doyle CM, Gaul BW, Lee C, Tiano HF, Morham SG, Smithies O, Langenbach R (2000) Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res 60: 4705-4708
7. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB, Lipsky PE (1998) Cyclooxygenase in biology and disease. FASEB J 12: 1063-1073
8. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN (1994) Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107: 1183-1188
9. Erovic BM, Woegerbauer M, Pammer J, Selzer E, Grasl M, Thurnher D (2008) Strong evidence for up-regulation of cyclooxygenase-1 in head and neck cancer. Eur J Clin Invest 38: 61-66
10. Gupta RA, Tejada LV, Tong BJ, Das SK, Morrow JD, Dey SK, DuBois RN (2003) Cyclooxygenase-1 is overexpressed and promotes angiogenic growth factor production in ovarian cancer. Cancer Res 63: 906-911
11. Houston A, O'Connell J (2004) The Fas signalling pathway and its role in the pathogenesis of cancer. Curr Opin Pharmacol 4: 321-326
12. Kamei D, Murakami M, Nakatani Y, Ishikawa Y, Ishii T, Kudo I (2003) Potential role of microsomal prostaglandin E synthase-1 in tumorigenesis. J Biol Chem 278: 19396-19405
13. Kawamori T, Kitamura T, Watanabe K, Uchiya N, Maruyama T, Narumiya S, Sugimura T, Wakabayashi K (2005) Prostaglandin E receptor subtype EP(1) deficiency inhibits colon cancer development. Carcinogenesis 26: 353-357
14. Kim H, Rhee SH, Pothoulakis C, Lamont JT (2007) Inflammation and apoptosis in Clostridium difficile enteritis is mediated by PGE2 upregulation of Fas ligand. Gastroenterology 133: 875-886
15. Lambert C, Landau AM, Desbarats J (2003) Fas - Beyond death: a regenerative role for Fas in the nervous system. Apoptosis 8: 551-562
16. Li H, Cai X, Fan X, Moquin B, Stoicov C, Houghton J (2008) Fas Ag - FasL coupling leads to ERK1/2-mediated proliferation of gastric mucosal cells. Am J Physiol Gastrointest Liver Physiol 294: G263-G275
17. Mann B, Gratchev A, Bohm C, Hanski ML, Foss HD, Demel G, Trojanek B, Schmidt-Wolf I, Stein H, Riecken EO, Buhr HJ, Hanski C (1999) FasL is more frequently expressed in liver metastases of colorectal cancer than in matched primary carcinomas. Br J Cancer 79: 1262-1269
18. Matsumoto N, Imamura R, Suda T (2007) Caspase-8- and JNK-dependent AP-1 activation is required for Fas ligand-induced IL-8 production. FEBS J 274: 2376-2384
19. Miyata Y, Kanda S, Maruta S, Matsuo T, Sakai H, Hayashi T, Kanetake H (2006) Relationship between prostaglandin E2 receptors and clinicopathologic features in human prostate cancer tissue. Urology 68: 1360-1365
20. Nagata S, Golstein P (1995) The Fas death factor. Science 267: 1449-1456
21. O'Connell J, Houston A, Bennett MW, O'Sullivan GC, Shanahan F (2001) Immune privilege or inflammation? Insights into the Fas ligand enigma. Nat Med 7: 271-274
22. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F (1996) The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 184: 1075-1082
23. Oikonomou E, Kothonidis K, Zografos G, Nasioulas G, Andera L, Pintzas A (2007) Newly established tumourigenic primary human colon cancer cell lines are sensitive to TRAIL-induced apoptosis in vitro and in vivo. Br J Cancer 97: 73-84
24. Okada K, Komuta K, Hashimoto S, Matsuzaki S, Kanematsu T, Koji T (2000) Frequency of apoptosis of tumor-infiltrating lymphocytes induced by fas counterattack in human colorectal carcinoma and its correlation with prognosis. Clin Cancer Res 6: 3560-3564
25. Osaki M, Kase S, Kodani I, Watanabe M, Adachi H, Ito H (2001) Expression of Fas and Fas ligand in human gastric adenomas and intestinal-type carcinomas: correlation with proliferation and apoptosis. Gastric Cancer 4: 198-205
26. Peter ME, Budd RC, Desbarats J, Hedrick SM, Hueber AO, Newell MK, Owen LB, Pope RM, Tschopp J, Wajant H, Wallach D, Wiltrout RH, Zornig M, Lynch DH (2007) The CD95 receptor: apoptosis revisited. Cell 129: 447-450
27. Porter BO, Malek TR (1999) Prostaglandin E2 inhibits T cell activation-induced apoptosis and Fas-mediated cellular cytotoxicity by blockade of Fas-ligand induction. Eur J Immunol 29: 2360-2365
28. Qiao L, Kozoni V, Tsioulias GJ, Koutsos MI, Hanif R, Shiff SJ, Rigas B (1995) Selected eicosanoids increase the proliferation rate of human colon carcinoma cell lines and mouse colonocytes in vivo. Biochim Biophys Acta 1258: 215-223
29. Rask K, Zhu Y, Wang W, Hedin L, Sundfeldt K (2006) Ovarian epithelial cancer: a role for PGE2-synthesis and signalling in malignant transformation and progression. Mol Cancer 5: 62
30. Restifo NP (2000) Not so Fas: re-evaluating the mechanisms of immune privilege and tumor escape. Nat Med 6: 493-495
31. Rigas B, Goldman IS, Levine L (1993) Altered eicosanoid levels in human colon cancer. J Lab Clin Med 122: 518-523
32. Ryan AE, Shanahan F, O'Connell J, Houston AM (2005) Addressing the 'Fas counterattack' controversy: blocking fas ligand expression suppresses tumor immune evasion of colon cancer in vivo. Cancer Res 65: 9817-9823
33. Sano H, Kawahito Y, Wilder RL, Hashiramoto A, Mukai S, Asai K, Kimura S, Kato H, Kondo M, Hla T (1995) Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 55: 3785-3789
34. Shoji Y, Takahashi M, Kitamura T, Watanabe K, Kawamori T, Maruyama T, Sugimoto Y, Negishi M, Narumiya S, Sugimura T, Wakabayashi K (2004) Downregulation of prostaglandin E receptor subtype EP3 during colon cancer development. Gut 53: 1151-1158
35. Waldner M, Schimanski CC, Neurath MF (2006) Colon cancer and the immune system: the role of tumor invading T cells. World J Gastroenterol 12: 7233-7238
36. Wang D, Dubois RN (2006) Prostaglandins and cancer. Gut 55: 115-122
37. Watanabe K, Kawamori T, Nakatsugi S, Ohta T, Ohuchida S, Yamamoto H, Maruyama T, Kondo K, Ushikubi F, Narumiya S, Sugimura T, Wakabayashi K (1999) Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis. Cancer Res 59: 5093-5096
38. Whiteside TL (2007) The role of death receptor ligands in shaping tumor microenvironment. Immunol Invest 36: 25-46
39. Williams CS, DuBois RN (1996) Prostaglandin endoperoxide synthase: why two isoforms? Am J Physiol 270: G393-G400
40. Younes M, Schwartz MR, Ertan A, Finnie D, Younes A (2000) Fas ligand expression in esophageal carcinomas and their lymph node metastases. Cancer 88: 524-528